HK28097A - Cyclosporin-containing pharmaceutical composition - Google Patents

Cyclosporin-containing pharmaceutical composition Download PDF

Info

Publication number
HK28097A
HK28097A HK28097A HK28097A HK28097A HK 28097 A HK28097 A HK 28097A HK 28097 A HK28097 A HK 28097A HK 28097 A HK28097 A HK 28097A HK 28097 A HK28097 A HK 28097A
Authority
HK
Hong Kong
Prior art keywords
cyclodextrin
cyclosporin
derivative
water
main chain
Prior art date
Application number
HK28097A
Other languages
German (de)
English (en)
French (fr)
Inventor
Kurihara Kozo
Murano Masaru
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK28097A publication Critical patent/HK28097A/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK28097A 1987-06-04 1997-03-06 Cyclosporin-containing pharmaceutical composition HK28097A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14070387 1987-06-04

Publications (1)

Publication Number Publication Date
HK28097A true HK28097A (en) 1997-03-06

Family

ID=15274767

Family Applications (1)

Application Number Title Priority Date Filing Date
HK28097A HK28097A (en) 1987-06-04 1997-03-06 Cyclosporin-containing pharmaceutical composition

Country Status (10)

Country Link
US (1) US5051402A (enExample)
EP (1) EP0294239B1 (enExample)
JP (1) JP2577049B2 (enExample)
AT (1) ATE72629T1 (enExample)
AU (1) AU607506B2 (enExample)
CA (1) CA1325973C (enExample)
DE (1) DE3868438D1 (enExample)
ES (1) ES2033429T3 (enExample)
GR (1) GR3004199T3 (enExample)
HK (1) HK28097A (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
JPH07111785B2 (ja) 1990-01-19 1995-11-29 富士通株式会社 光ディスク
US5227372A (en) * 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
HU208491B (en) * 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
FR2670629B1 (fr) * 1990-12-17 1995-03-10 Moving Magnet Tech Actionneur electromagnetique monophase rotatif.
DE69222150T2 (de) * 1991-01-25 1998-01-15 Fujisawa Pharmaceutical Co Prozess zur produktion von cyclosporin-a und/oder c
ES2098739T3 (es) * 1992-05-13 1997-05-01 Sandoz Ltd Composiciones oftalmicas conteniendo una cyclosporin.
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
NZ247516A (en) * 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US5739105A (en) * 1994-06-01 1998-04-14 Yuhan Corporation Cyclosporin containing composition and process for the preparation thereof
KR0167613B1 (ko) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
JP3934705B2 (ja) * 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
JP2007056045A (ja) * 1995-05-26 2007-03-08 Nobaruteisu Fuaama Kk サイクロデキストリン組成物
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
EP1331002A3 (en) 1997-01-30 2004-01-14 Novartis AG Oil-free pharmaceutical compositions containing cyclosporin A
NZ328751A (en) 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
CA2298572C (en) 1997-10-08 2002-04-09 Isotechnika Inc. Deuterated cyclosporine analogs and their use as immunomodulating agents
TW581681B (en) * 1998-02-20 2004-04-01 Nektar Therapeutics Liquid crystal forms of cyclosporin
WO2000012137A1 (en) 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
DE60233150D1 (de) * 2001-10-19 2009-09-10 Isotechnika Inc Neue cyclosporin-analoge mikroemulsionsvorkonzentrate
PT1436321E (pt) 2001-10-19 2006-10-31 Isotechnika Inc Sintese de analogos de ciclosporina
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
CN1905870A (zh) 2003-11-21 2007-01-31 康宾纳特克斯公司 用于治疗炎性病症的方法和试剂
US7691812B2 (en) * 2004-11-04 2010-04-06 Trustees Of The University Of Pennsylvania Methods for inhibiting growth of prolactin-responsive cancer cells with cyclosporine A or other cyclophilin inhibitors
US20070015693A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7202209B2 (en) * 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) * 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7276476B2 (en) * 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
CA2615990A1 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
TWI435729B (zh) 2005-11-09 2014-05-01 Combinatorx Inc 治療病症之方法,組合物及套組
DE102006051512A1 (de) 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
FI118537B (fi) * 2006-03-08 2007-12-14 Kuopion Yliopisto Menetelmä syklodekstriinin kompleksoitumisen lisäämiseksi
AU2016203191B2 (en) * 2006-07-25 2018-03-01 Allergan, Inc. Cyclosporin compositions
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
US20080146497A1 (en) * 2006-07-25 2008-06-19 Graham Richard S Cyclosporin Compositions
CN101896160A (zh) * 2006-10-17 2010-11-24 阿勒根公司 环胞菌素组合物
MX2010003364A (es) 2007-10-08 2010-07-06 Lux Biosciences Inc Composiciones oftalmicas que comprenden inhibidores de calcineurina o inhibidores de mtor.
US20100016219A1 (en) * 2008-07-19 2010-01-21 Jerry Zhang Ophthalmic compositions containing solubilized cyclosporin
JP2012529509A (ja) 2009-06-09 2012-11-22 ラックス・バイオサイエンシーズ・インコーポレイテッド 眼科用用途のための局所薬物送達システム
JP2014522849A (ja) * 2011-06-29 2014-09-08 アラーガン インコーポレイテッド ヒドロキシステアリン酸マクロゴール15製剤
RU2017146716A (ru) * 2015-05-29 2019-07-02 Окулис Эхф. Способ образования наночастиц циклоспорина а/ циклодекстрина
CN105997863B (zh) * 2016-07-21 2018-09-04 河南省眼科研究所 环孢素a滴眼液及其制备方法
SI3548091T1 (sl) 2016-11-29 2022-04-29 Oculis SA Priprava trdnih ciklodekstrinskih kompleksov za dostavo oftalmične farmacevtske učinkovine
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
CN114040766A (zh) 2019-07-01 2022-02-11 奥库里斯公司 用于稳定包含药物的水性组合物pH的方法
CN112724200B (zh) * 2019-10-28 2022-09-27 上海云泽生物科技有限公司 一种稳定环孢霉素a的稀释液及其应用
WO2022098122A1 (ko) 2020-11-09 2022-05-12 주식회사 스카이테라퓨틱스 고상의 사이클로스포린 a 및 이를 포함하는 분산 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117118A (en) * 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
PH19156A (en) * 1982-02-01 1986-01-15 Sandoz Ltd Dihydrocyclosporin d in the treatment of multiple sclerosis
DE3372705D1 (en) * 1982-04-30 1987-09-03 Takeda Chemical Industries Ltd Pharmaceutical composition and its use
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
EP0170623B1 (en) * 1984-08-02 1990-11-28 Sandoz Ag Novel pharmaceutical use of (nva)2-cyclosporine

Also Published As

Publication number Publication date
ATE72629T1 (de) 1992-03-15
DE3868438D1 (de) 1992-03-26
EP0294239B1 (en) 1992-02-19
CA1325973C (en) 1994-01-11
JPS6485921A (en) 1989-03-30
ES2033429T3 (es) 1993-03-16
GR3004199T3 (enExample) 1993-03-31
JP2577049B2 (ja) 1997-01-29
EP0294239A1 (en) 1988-12-07
US5051402A (en) 1991-09-24
AU607506B2 (en) 1991-03-07
AU1738688A (en) 1988-12-22

Similar Documents

Publication Publication Date Title
EP0294239B1 (en) Cyclosporin-containing pharmaceutical composition
CA2172159C (en) Improved pharmaceutical formulation
JP2617958B2 (ja) 薬理活性剤のヒドロゾルおよびそれを含有する医薬組成物
JP5656692B2 (ja) アミオダロンおよびスルホアルキルエーテルシクロデキストリンを含む製剤
EP0308181A1 (en) Trans-mucosal delivery formulations and a method for preparation thereof
HK35697A (en) Cyclosporin compositions
KR20010031967A (ko) 시클로덱스트린 및 탁소이드를 함유하는 약제학적 조성물
JP2001510810A (ja) 製剤活性成分を水中又は水性ビヒクル中に可溶化する方法
RU2322254C2 (ru) Жидкий препарат, содержащий олигопептиды и этерифицированный циклодекстрин
EA034565B1 (ru) Композиции левосимендана для внутривенного введения в виде инфузии или инъекции и концентрата для инфузии
JPH0558906A (ja) シクロスポリン点眼製剤
TW200306314A (en) Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
SIEFERT et al. Influence of cyclodextrins on the in vitro corneal permeability and in vivo ocular distribution of thalidomide
CN1046516C (zh) 化合物dx-52-1的稳定方法和其冻干组合物
JPH0948737A (ja) サイクロデキストリン組成物
Kim et al. Development of digoxin dry elixir as a novel dosage form using a spray-drying technique
EP1313449B1 (en) Amphotericin b structured emulsion
AU2001280084A1 (en) Amphotericin B structured emulsion
POURRAT et al. Stabilization of Octastation, a Somatostatin Analogue. Preparation of Freeze-Dried Products for Parenteral Injection
RU2634267C2 (ru) Водный офтальмологический раствор на основе циклоспорина a
US20050043225A1 (en) Pharmaceutical formulation
IBRAHIMC Stabilization of Octastatin®, a Somatostatin Analogue. Preparation of Freeze-Dried Products for Parenteral Injection

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20080605